Introduction {#s0005}
============

The P2Y~14~ receptor (P2Y~14~R) is a member of P2-purigenic receptors, which has been regarded as inhibitory adenylate cyclae G-protein (Gi)-coupled receptor. It inhibits the production of 3′,5′-cyclicadenosine monophosphate (cAMP) through Gi protein, which could be activated by endogenous uidine diphosphate (UDP)-sugars. Activation of P2Y~14~R has been regarded to be associated with proinflammatory reactions, leading to neutrophil chemotaxis and mast cell degranulation [@b0005], [@b0010], [@b0015], [@b0020]. P2Y~14~R is distributed among a variety of immune cells and is expressed in extensive tissues [@b0025], [@b0030], [@b0035].

Several animal studies have demonstrated the value of P2Y~14~R as potential therapeutic target for recruitment of macrophages to liver, induction of insulin resistance in diabetes and local inflammation [@b0040], [@b0045], [@b0050]. However, there are few studies focused on relationship between P2Y~14~R and acute gouty arthritis, which is a group of characteristic inflammatory reactions caused by innate immune disorders. Acute gouty arthritis is triggered by deposition of monosodium urate crystals (MSU) in the joint, resulting from the activation of Nod-like receptor 3 (NLRP3) inflammasome [@b0055], [@b0060], [@b0065].

Our recent studies have showed that inhibition of NLRP3-mediated pyroptosis is a viable strategy for the prevention and treatment of acute gouty arthritis [@b0070], [@b0075]. Till now, the treatment of gout still lacks the ideal drug. Previous study suggested that MSU can induce high expression of P2Y~14~R in human keratinocytes [@b0080], offering strong evidence that P2Y~14~R might play causal role in MSU-related diseases. Meanwhile, the activation of P2Y~14~R is closely related to the content of intracellular cAMP, which was demonstrated to negatively regulate NLRP3 inflammasome [@b0085], involved in inflammatory, diabetes, immune processes and other related complications [@b0090], [@b0095]. Therefore, P2Y~14~R is likely to regulate the inflammatory response through NLRP3 inflammasome via cAMP in acute gouty arthritis.

To date, the current researches on P2Y~14~R antagonists only reported three types of compounds including pyrimidine piperidine, 2-naphthoic acid and 3-substituted benzoic acid [@b0035], [@b0045], [@b0100], [@b0105], [@b0110]. Among them, the most active and selective P2Y~14~R antagonist is (4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (PPTN, IC~50~ = 4 nM). However, the currently reported antagonists represented by 2-naphthoic acid suffered from poor solubility, low oral bioavailability, and high difficulty in synthesizing raw materials, bringing greater difficulties to further discussion of structure-activity relationship and biological evaluation [@b0110]. In addition, based on P2Y~14~R homology models, a novel P2Y~14~R antagonists with scaffold, 3-(4-phenyl-1*H*-1,2,3-triazol-1-yl)-5-phenyl substituted benzoic acid was reported by Jacobson and co-workers using molecular docking and molecular dynamics (MD) simulation approaches. The identified P2Y~14~R antagonists showed quite acceptable binding affinities and the IC~50~ value of most potent P2Y~14~R antagonist was 31.7 nM. Based on these observations, there remains ongoing need to explore potent P2Y~14~R antagonists with novel chemical architectures. Besides, the development of promising P2Y~14~R antagonists could be a reasonable way for the treatment of gout.

Due to the high cost and time-consuming of high-throughput screening (HTS), virtual screening (VS) has aroused widespread concerns and been widely used in lead compound identifications of drug discovery [@b0115], [@b0120]. For the crystal structures of P2Y~14~R has not yet been reported, the structure-based virtual screening (SBVS) can be used for finding novel P2Y~14~R antagonists with diverse chemical scaffolds based on well-established homology modes of P2Y~14~R [@b0100], [@b0105], [@b0110].

To our knowledge, this is the first case to carry out a molecular docking strategy to massively screen a commercial library for finding novel P2Y~14~R antagonists based on P2Y~14~R homology models. Two well-prepared and minimized P2Y~14~R homology models (HM1 and HM2) [@b0105] were used to screen the ChemDiv database. 19 diverse compounds were selected using drug-likeness properties prediction, REOS filtering, core scaffold clustering and purchased for biological testing. 10 of them (VS hit rate \> 50%) exhibited significant antagonistic activity against P2Y~14~R (IC~50~ \< 50 nM) and the most potent lead, compound **8** displayed a quite satisfactory antagonistic activity with IC~50~ value of 2.46 nM. Then, the feasibility of compound **8** as a drug candidate for treating gout treatment was investigated through a series of pharmacodynamics and mechanism of action. The results demonstrated that compound **8** restrained MSU-induced pyroptosis of THP-1 cells through blocking the activation of NLRP3 inflammasome, which was attributed to its inhibitory effects on P2Y14R-cAMP pathways. Finally, the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) binding free energy calculations/decompositions were employed to preliminarily detect the interaction patterns between P2Y~14~R and two most potent hits (compounds **8** and **18**). The key favorable residues for P2Y~14~R antagonists binding were detected and discussed. These findings may guide us to discovery more promising P2Y~14~R antagonists for treating acute gouty arthritis in the near future.

Materials and methods {#s0010}
=====================

P2Y~14~R homology models for docking-based virtual screening {#s0015}
------------------------------------------------------------

The P2Y~14~R homology models (HM1 and HM2) [@b0105] well established by Trujillo *et al.* were selected, optimized and applied in the Glide docking-based VS campaign of Schrödinger 9.0 software [@b0125]. By utilizing the *Protein Preparation Wizard* module of Schrödinger 9.0, all water molecules were removed, the broken side chains were repaired and missing hydrogen atoms were added. Then, using the OPLS2005 force field, the partial charges and protonation states were assigned for each homology model.

Molecular docking-based virtual screening procedure {#s0020}
---------------------------------------------------

First of all, the *Receptor Grid Generation* module of Glide of Schrödinger 9.0 was used to generate binding site/pocket for molecular docking. The binding pocket size was set to 10 Å × 10 Å × 10 Å and centered on the centroid of the ligand in each P2Y~14~R homology model.

Then, the ChemDiv library including more than 2 million compounds was selected as screening database and screened against two P2Y~14~R homology models. Using the *LigPrep* mode of Glide, all compounds in the ChemDiv database were preprocessed carefully. For each compound in ChemDiv, the tautomers were generated at pH = 7.0 ± 2.0 and the different combinations of chiralities were also generated by setting the maximum number of stereoisomers to 32 by using *Epik*. At last, the final well-prepared ChemDiv database comprising more than 2.6 million compounds was set to Glide docking-based VS pipeline.

P2Y14R inhibitory activities screening {#s0025}
--------------------------------------

HEK293 cell lines stably expressing the P2Y~14~R were purchased from Keygen Biotech Co, ltd. Cells were plated in 384-well plates approximately 24 h before the assay at the density of 10,000 cells per well. Before assay, cells were briefly washed with phosphate-buffered saline solution to remove traces of serum and then incubated with 7.5 μL induction buffer contained 30 μM Forskolin (Med Chem Express, Cat. \#HY-15371), 10 μM UDP-glucose (Sigma Aldrich, Cat. \# U4625) and various concentrations of test compounds (0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM) for 30 min at 37 °C, each concentration of 3 repetitions. P2Y~14~R inhibitory activities at each concentration were evaluated by detecting cAMP levels in order to calculate IC~50~ values.

Cell culture {#s0030}
------------

THP-1 cell line purchased from American Type Culture Collection (Manassas, VA, USA) was cultured and stimulated with phorbol 12-myristate 13-acetate (PMA) as previous studies. Then, cells were pre-treated with Compound 8 or PPTN for 1 h, followed by the stimulation with MSU (500 μg/ml) for 12 h. Subsequently, the culture supernatants were collected for further investigation.

Measurements of IL-1β and cAMP {#s0035}
------------------------------

IL-1β concentrations in culture supernatants and cAMP levels in cell lysis were detected with ELISA Kit (Neobioscience, Shenzhen, China) or cAMP-Glo™ Assay Kit (Promega, WI, USA).

Pyroptosis assay {#s0040}
----------------

For pyroptosis analysis, active Caspase-1 and PI fluorescence of samples were measured using flow cytometry. Active caspase-1 was detected with FLICA 660 Caspase-1 Detection Kit (Immuno Chemistry Technologoes, USA), and propidium iodide (PI) staining was used to assess the integrity of cellular membrane.

Immunofluorescence {#s0045}
------------------

After MSU stimulation, the cells were 4% paraformaldehyde fixed for 20--30 min. Permeabilization was performed with 0.3%--0.5% Triton X-100 for 20--30 min. When blocking for 1 h to avoid non-specific protein interactions, the samples were incubated with the primary antibody and secondary antibodies in sequence as previous studies. Fluorescent images were visualized by confocal laser scanning microscope (Fluoview, FV1000, Olympus, Japan).

Western blot {#s0050}
------------

The THP-1 cells collected from each group were lysed in a RIPA buffer (Sigma, St. Louis, MO, USA). Samples containing approximately 50 mg protein was separated by 8--12% SDS-PAGE followed by the transference to polyvinylidene fluoride membranes (Millipore Corporation, MA, USA). Subsequently, PVDF membranes were treated with primary antibodies overnight at 4 °C after being blocked. The membranes were washed three times with Tris buffer saline-Tween20 (TBST), followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies for 2 h. Finally, protein bands were visualized with an enhanced chemiluminescence (ECL) system (Keygen Biotech, China) and scanned with a Chemiluminescence gel imaging system (Tanon-5200Multi, China).

Statistical analysis {#s0055}
--------------------

The data are expressed as mean values ± SDs. Data analyses were performed by one-way ANOVA with Tukey multiple comparison test (Graphpad Prism 7.0a), with p \< 0.05 considered as significant.

Results and discussion {#s0060}
======================

Molecular docking-based virtual screening pipeline {#s0065}
--------------------------------------------------

Two well-established P2Y~14~R homology models (HM1 and HM2) [@b0105] proposed by Trujillo *et al.* were selected and minimized for the following docking-based virtual screening pipeline ([Fig. 1](#f0005){ref-type="fig"}). Three scoring functions of Glide docking (HTVS, SP XP) were applied to perform the sequential VS strategy [@b0125]. The 50,000 highest -ranked compounds of the prepared ChemDiv database predicted by HTVS were re-docked using SP scoring mode. Then, the 5000 highest-ranked compounds of SP were re-calculated using the XP scoring function. At last, 1000 highest -ranked compounds were obtained for each P2Y~14~R homology model. Followed by removing duplicates, Lipinski "Rule-of Five" filter [@b0130] and drug-likeness models built in our previous studies [@b0135], [@b0140], [@b0145], [@b0150], the compounds with reactive, undesirable functional groups or toxic were also deleted by applying REOS criterion [@b0155]. Then, the compounds with less than two chiral centers were retained and then the remaining compounds were clustered using the *Tanimoto coefficient* evaluated based on *MACCS* structural keys (*Tanimoto coefficient* cut off value = 0.7). At last, 19 compounds were selected from ChemDiv database and purchased for experimental testing ([Table 1](#t0005){ref-type="table"}).Fig. 1The predicted binding poses and interaction patterns of (a) homology model 1 (HM1) and (b) homology model 2 (HM2) of P2Y14R. (The co-ligands in HM1 and HM2 are UDP-[@b0005] glucose and UDP, respectively).Table 1Biological activities, representative molecular properties and key parameters identified in docking-based VS of the 19 purchased compounds from ChemDiv database.CompdID_number[a](#tblfn1){ref-type="table-fn"}IC~50~(nM)docking score[b](#tblfn2){ref-type="table-fn"}MWlog*P*log*S*model**1**1278--0075ND−14.97299.301.20−2.29HM1**2**1683--709335.4−12.76351.383.11−4.46HM1**3**2372--3546ND−16.34303.292.18−3.68HM2**4**3473--258928.7−14.39349.433.54−4.83HM2**5**3975--0036ND−15.82344.112.23−4.00HM2**6**4393--001945.5−14.34451.495.37−6.67HM1**7**5369--006316.5−15.10329.310.74−2.13HM2**8**6521--00662.46−13.06305.332.81−3.79HM1**9**7244--006718.6−14.72273.293.07−2.40HM2**10**8011--47605.35−14.22362.432.87−5.92HM1**11**8012--2120ND−12.98389.423.77−4.01HM1**12**8013--6020ND−12.35344.363.89−4.31HM1**13**8020--2337ND−14.06231.171.21−2.16HM2**14**C301-466012.39−15.15387.462.50−5.52HM2**15**F293-0086ND−15.51404.514.12−4.81HM2**16**F293-0205ND−14.64438.534.51−5.53HM2**17**K783-4166ND−12.64339.734.30−5.62HM1**18**Y040-30785.12−13.60314.343.90−5.10HM2**19**Y041-23087.71−15.10396.353.55−5.82HM1**20**PPTN[c](#tblfn3){ref-type="table-fn"}2.74475.503.80−10.42[^2][^3][^4]

In vitro P2Y~14~R inhibitory activities screening {#s0070}
-------------------------------------------------

P2Y~14~R inhibitory activities of testing compounds were determined based on production of cAMP in a HEK293 cell line stably expressing P2Y~14~R. The results were listed in [Table 1](#t0005){ref-type="table"}. As can be seen in [Table 1](#t0005){ref-type="table"}, 10 of 19 purchased compounds (VS hit rate = 52.63%) showed quite acceptable inhibitory activity (IC~50~ \< 50 nM) for P2Y~14~R. The chemical structures of 10 identified P2Y~14~R antagonists with IC~50~ value below 50 nM are shown in [Fig. 2](#f0010){ref-type="fig"} and those of the remaining compounds were shown in the [Fig. S1](#s0100){ref-type="sec"} in the [Supporting Information](#s0100){ref-type="sec"}. Among them, four compounds (compound **8**, **10**, **18** and **19**) exhibited satisfactory antagonistic activity of P2Y~14~R (IC~50~ value below 10 nM, [Fig. 3](#f0015){ref-type="fig"}), and compound **8** showed the most potent antagonistic activity (IC~50~ = 2.46 nM). The schematic representations of the predicted binding poses and interaction patterns between the P2Y~14~R and the two most potent identified antagonists (compounds **8** and **18**) are depicted in [Fig. 4](#f0020){ref-type="fig"}.Fig. 2Structures of 10 potent antagonists of P2Y~14~R (IC~50~ \< 50 nM) identified from Glide docking-based VS.Fig. 3Fluorescent assay of P2Y~14~R binding affinities (IC~50~ curves) of four identified P2Y~14~R antagonists (compounds **8**, **10**, **18** and **19**) with IC~50~ value below 10 nM, PPTN was run as positive control.Fig. 4(a) The predicted conformations of compounds **8** and **18** derived from Glide docking (the complexes of compound **8**-P2Y~14~R was colored in golden and compound **18**-P2Y~14~R was colored in green) and (b) predicted interaction patterns for compounds **8** and **18** in the binding pocket by applying HM1 and HM2 as docking structure, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

In vitro anti-inflammatory effects of compound 8 through regulation of cAMP and NLRP3 inflammasome {#s0075}
--------------------------------------------------------------------------------------------------

As shown in [Fig. 5](#f0025){ref-type="fig"}, cAMP concentrations were significantly decreased after MSU stimulation, which was reversed by pre-treatment of compound **8** and PPTN. More importantly, MSU administration led to a significant increase in the proportion of pyroptotic cells characterized by Caspase-1/PI double positive staining analyzed by flow cytometry. As expected, this alternation was also improved in compound **8** and PPTN treated cells ([Fig. 6](#f0030){ref-type="fig"}a and b). Consistently, IL-1β levels in the supernatant of THP-1 cell culture medium were obviously increased in model group. Both compound **8** and PPTN interventions apparently inhibited the release of IL-1β, reflecting the mitigation of inflammation caused by MSU ([Fig. 6](#f0030){ref-type="fig"}c). As shown in [Fig. 7](#f0035){ref-type="fig"}, protein expressions of NLRP3, ASC (apoptosis-associated speck-like protein containing a CARD) and Caspase-1 p20 were apparently increased in THP-1 cells with MSU stimulation. And aforementioned alterations were reversed by pre-treatment of compound **8** and PPTN.Fig. 5Effects of compound **8** and PPTN on levels of cAMP in MSU-treated THP-1 cells. Compared with Control group: ^\#\#\#^*P* \< 0.001. Compared with Model group: \**P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001. Each group (n = 4).Fig. 6Effects of compound **8** and PPTN on proportions of Caspase-1 single positive and Caspase-1/PI double positive cells (a and b), as well as levels of IL-1β (c) in cell culture supernatants of MSU-treated THP-1 cells. Compared with Control group: ^\#\#\#^*P* \< 0.001. Compared with Model group: \**P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001. Each group (n = 4).Fig. 7Effects of compound **8** and PPTN on protein expressions of NLRP3, ASC and Caspase-1 (p20) (a and b) in MSU-treated THP-1 cells. Compared with Control group: ^\#\#\#^*P* \< 0.001. Compared with Model group: \**P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001. Each group (n = 4). Representative confocal microscopy photographs of THP-1 cells with immunofluorescence changes are presented (c).

On the other hand, inhibitory effect of compound **8** on NLRP3 inflammasome was also confirmed by immunofluorescence data ([Fig. 7](#f0035){ref-type="fig"}c). When compared to control cells, model cells apparently showed higher fluorescence intensity in NLRP3 and ASC staining without observed difference in DAPI (4′,6-diamidino-2-phenylindole) intensity.

Primary structure-activity relationship discussions using MM/GBSA free energy decompositions {#s0080}
--------------------------------------------------------------------------------------------

For exploring the detected antagonistic activity differences, the most potent VS hits (compounds **8** and **18)** of P2Y~14~R were selected and docked into the respectively binding pocket of P2Y~14~R homology models (HM1 and HM2) using *Glide* XP scoring mode. In order to investigate the interaction pattern between PPTN and P2Y14 receptor, the PPTN was docked into the binding pocket of HM1 and HM2 using SP and XP scoring modes of Glide docking. The docking results demonstrated that PPTN cannot produce acceptable docking poses against P2Y14 receptor. Considering the higher protein flexibility of P2Y14 receptor, the PPTN may adopt quite distinct binding mode with P2Y14 receptor, compared with assayed compounds in our study.

By employing the MM/GBSA approach [@b0160], [@b0165], [@b0170], the predicted binding poses of compounds **8** and **18** interacting with P2Y~14~R were optimized and rescored. The predicted total binding free energies using MM/GBSA rescoring of compounds **8** and **18** were −42.85 and −61.20 kcal/mol, respectively ([Table 2](#t0010){ref-type="table"}). Then, for quantitatively discerning the contribution of each key residues of P2Y~14~R binding with compounds **8** and **18**, the antagonist-residues interaction spectra were depicted and analyzed. As can be seen in [Fig. 8](#f0040){ref-type="fig"}a, two most potent antagonists of P2Y~14~R have quite distinct binding sites in the binding pocket of P2Y~14~R. For example, the residues ofVal99, Asn156, Cys172, Lys176, Arg253 and Gln260 play as the key residues for the compound **8** binding with P2Y~14~R, and their favorable contributions to the total binding energy (Δ*G*~pred~) are all lower than −1.5 kcal/mol. Compared with compound **8**, compound **18** has quite different favorable binding residues. The dominant residues of compound **18** interacting with P2Y~14~R are Lys77, Ala98, Phe101, Arg253, Gln260 and Lys277. The same key residues for compounds **8** and **18** binding with P2Y~14~R are Arg253 and Gln260. The energy contributions of Arg253 and Gln260 for compounds **8** were −11.07 and −4.20 kcal/mol ([Fig. 8](#f0040){ref-type="fig"}a), and those for compound **18** were −10.30 and −3.82 kcal/mol ([Fig. 8](#f0040){ref-type="fig"}b), respectively. Considering inherent high flexibility of P2Y~14~R structure, we found that maintaining stable/strong interactions with these favorable residues (Lys77, Ala98, Val99, Phe101, Asn156, Cys172, Lys176, Arg253, Gln260 and Lys277) are the requirements for obtaining promising P2Y~14~R antagonists. This finding will provide some clues to design/develop more optimal antagonists of P2Y~14~R in the lead optimization stage.Table 2The predicted binding free energies using MM/GBSA rescoring of compounds 8 and 18.CompdPolar contributionsNonpolar contributionsΔ*G*~pred~[e](#tblfn8){ref-type="table-fn"}Δ*E*~ele~[a](#tblfn4){ref-type="table-fn"}Δ*G*~GB1~[b](#tblfn5){ref-type="table-fn"}Δ*E*~vdw~[c](#tblfn6){ref-type="table-fn"}Δ*G*~SA~[d](#tblfn7){ref-type="table-fn"}**8**−698.72699.19−36.92−6.40−42.85**18**−388.98373.62−39.38−6.46−61.20[^5][^6][^7][^8][^9]Fig. 8(a) The binding poses of compounds **8** and **18** optimized from the MM/GBSA calculations (the favorable residues for compounds **8** and **18** binding with P2Y~14~R are colored in golden and green, respectively. The same key residues for two compounds are colored in red), (b) the antagonist-residues interaction spectra of compounds **8** and **18**.

Conclusions {#s0085}
===========

In the current work, we adopted Glide docking-based virtual screening strategy for finding potent P2Y~14~R antagonists using two well-established P2Y~14~R homology models. 19 potential hits with quite novel chemical scaffolds were set to antagonistic activity testing. 10 of them revealed significant antagonistic activity against P2Y~14~R. The IC~50~ of the most potent identified P2Y~14~R antagonist (compound **8)** can reach 2 nM, which was higher than the previously reported 2-naphthoic acid compound PPTN. To further confirm its feasibility as a drug for the prevention and treatment of acute gouty arthritis, we established a THP-1 cell model exposed to MSU to simulate acute gouty arthritis. The results demonstrated that compound **8** can significantly restore cAMP production and reduce IL-1β secretion. More importantly, compound **8** blocked the pyroptosis of THP-1 cells and inhibited the activation of NLRP3 inflamasome. These findings indicate that the compound **8** might be applied as a good lead compound for further modification/optimization for the treatment of acute gouty arthritis.
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